TY - JOUR
T1 - Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus
AU - Pranzatelli, Michael R.
AU - Tate, Elizabeth D.
AU - Shenoy, Shalini
AU - Travelstead, Anna L.
PY - 2012/6/1
Y1 - 2012/6/1
N2 - Ofatumumab is a fully human anti-CD20 monoclonal antibody in phase II-III trials for various autoimmune and lymphoreticular diseases. We used it to treat a rituximab-allergic child with severe, chronic-relapsing, opsoclonus-myoclonus syndrome (OMS), characterized by persistent cerebrospinal fluid (CSF) B-cell expansion and T-cell dysregulation. He had relapsed despite chemotherapy, plasma exchange with immunoadsorption, and resection of ganglioneuroblastoma, detected 3 years after OMS onset. The four ofatumumab infusions (1,195mg/m 2 total dose) were well tolerated, and CSF B-cell expansion was eliminated. No further relapses have occurred in 3 years, but he remains on low-dose ACTH with neuropsychiatric residuals of OMS.
AB - Ofatumumab is a fully human anti-CD20 monoclonal antibody in phase II-III trials for various autoimmune and lymphoreticular diseases. We used it to treat a rituximab-allergic child with severe, chronic-relapsing, opsoclonus-myoclonus syndrome (OMS), characterized by persistent cerebrospinal fluid (CSF) B-cell expansion and T-cell dysregulation. He had relapsed despite chemotherapy, plasma exchange with immunoadsorption, and resection of ganglioneuroblastoma, detected 3 years after OMS onset. The four ofatumumab infusions (1,195mg/m 2 total dose) were well tolerated, and CSF B-cell expansion was eliminated. No further relapses have occurred in 3 years, but he remains on low-dose ACTH with neuropsychiatric residuals of OMS.
KW - Anti-B-cell therapy
KW - Ganglioneuroblastoma
KW - Paraneoplastic disorder
KW - Plasma exchange/immunoadsorption
UR - http://www.scopus.com/inward/record.url?scp=84858667269&partnerID=8YFLogxK
U2 - 10.1002/pbc.23187
DO - 10.1002/pbc.23187
M3 - Article
C2 - 21618414
AN - SCOPUS:84858667269
VL - 58
SP - 988
EP - 991
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
SN - 1545-5009
IS - 6
ER -